サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551477

胆管がんの世界市場

Bile Duct Cancer

出版日
ページ情報
英文 392 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
胆管がんの世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 392 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胆管がんの世界市場は2030年までに3億8,260万米ドルに達する見込み

2023年に2億5,820万米ドルと推定された胆管がんの世界市場は、2023年から2030年にかけてCAGR 5.8%で成長し、2030年には3億8,260万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外科療法は、CAGR 7.3％を記録し、分析期間終了時には1億5,410万米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 5.9％と推定されます。

米国市場は7,030万米ドルと推定、中国はCAGR 9.6％で成長すると予測

米国の胆管がん市場は2023年に7,030万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8,250万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.3％と5.9％と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の胆管がん市場- 主要動向と促進要因のまとめ

胆管がんの何が複雑で課題なのか？

胆管がんとしても知られる胆管がんは、肝臓から胆嚢や小腸に胆汁を運ぶ細い管である胆管に発生する、まれではあるが非常に侵攻性の高いがんです。しかし、このがんが特に難しいのはなぜだろうか？胆管がんは初期段階では無症状であることが多く、進行するまで発見が難しいです。黄疸、腹痛、原因不明の体重減少などの症状が現れる頃には、すでに治療の選択肢が限られている段階であることが多いです。さらに、胆管は解剖学的に肝臓の奥深くにあり、重要な臓器に囲まれているため、診断も外科的介入も複雑になります。MRI、CTスキャン、胆管造影のような特殊な技術などの画像検査は腫瘍の位置を特定するために不可欠であるが、胆道系の複雑な構造のため、結論が出なかったり、解釈が難しかったりします。この複雑さは、胆管がんとの闘いにおいて、より効果的な診断ツールと早期発見戦略の緊急の必要性を強調しています。

なぜ胆管がんに対する治療の選択肢は限られているのか？

がん治療が進歩しているにもかかわらず、胆管がんの治療法が限られているのはなぜでしょうか？その第一の理由は、この病気が希少であるため、一般的ながんに比べて広範な調査や臨床試験が行われていないことです。限局性胆管がんの標準的治療は手術、特に胆管や肝臓の患部の切除です。しかし、手術が実行可能なのは、がんが早期に発見され、他の臓器に転移していない場合のみです。残念ながら、診断が遅かったために、多くの患者は手術の対象とならず、化学療法と放射線療法が治療の主軸となります。これらの治療法は、病気の進行を遅らせる効果がある場合もあるが、治癒には至らず、しばしば重大な副作用を伴う。最近の動向では、健康な組織を温存しながらがん細胞をより正確に攻撃することを目的とした標的療法や免疫療法の開発が進んでいます。FGFR2阻害剤やIDH1阻害剤など、胆管がんに関連する特定の遺伝子変異を標的とした治療薬は臨床試験で有望視されており、将来的にはより効果的な治療が期待できます。しかしながら、様々なサブタイプや分子プロファイルを持つがんの不均一性は、万能の治療アプローチの開発を複雑にしています。

胆管がん研究の最新動向は？

胆管がんの調査は激化しているが、患者にとっての展望を変える可能性のある最新の動向とは何か？重要な動向の一つは、個別化医療への注目の高まりです。各患者のがんの特徴を理解する上で、遺伝子プロファイリングの重要性を認識する研究者が増えています。特定の遺伝子変異や分子標的を特定することで、従来の化学療法よりも効果的な個別化治療計画を立てることができます。もうひとつの動向は、免疫療法（身体の免疫システムを活用してがんと闘う）の探求です。胆管がんではまだ初期段階であるが、臨床試験では免疫チェックポイント阻害剤やその他の免疫療法剤が患者の予後を改善する可能性が検討されています。さらに、早期発見法の改善も進められており、科学者たちは、侵襲性が低く、より正確な診断検査につながる可能性のある血液や胆汁中のバイオマーカーを探索しています。PET/CTスキャンや強化MRI技術などの画像技術の進歩も、より早期で正確な診断に貢献しています。さらに、血液中のがん細胞やDNA断片を検出するリキッドバイオプシーの役割は、病気の進行や治療への反応をリアルタイムでモニタリングする上で画期的なものとなる可能性があり、研究が進められています。

胆管がん治療市場の成長を促進する要因は何か？

胆管がん治療市場の成長は、革新的な治療や診断に対する需要の増加を反映するいくつかの要因によって牽引されています。主な促進要因の1つは、ゲノム研究の進歩であり、これによって特定の薬剤を標的とすることができる実用的な遺伝子変異が同定されるようになった。これにより、標的治療の開発に新たな道が開かれ、特定の遺伝子プロファイルを持つ患者により効果的な治療選択肢が提供されるようになった。さらに、胆管がんの有病率が上昇し、特に肝フルク感染などの危険因子による罹患率が高い地域では、より良い治療オプションへの需要が高まっています。もう一つの重要な要因は、ヘルスケアプロバイダーや患者の間でこの病気に対する認識が高まり、早期診断や早期段階での介入が重視されるようになっていることです。次世代シーケンシングや画像診断技術の向上など、高度な診断技術の利用可能性が高まっていることも、より正確で早期発見を可能にし、市場の成長に寄与しています。さらに、臨床試験の拡大や新しい治療法の開発への製薬会社の関与も、新規治療法のイントロダクションを加速させています。このような要因が重なることで、胆管がん治療市場は大きな成長を遂げ、将来的には患者の予後が改善することが期待されています。

調査対象企業の例（全56件）

  • AbbVie Inc.
  • Accord Healthcare, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CONMED Corporation
  • Delcath Systems Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Intercept Pharmaceuticals, Inc.
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals USA, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26684

Global Bile Duct Cancer Market to Reach US$382.6 Million by 2030

The global market for Bile Duct Cancer estimated at US$258.2 Million in the year 2023, is expected to reach US$382.6 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Surgical Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$154.1 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$70.3 Million While China is Forecast to Grow at 9.6% CAGR

The Bile Duct Cancer market in the U.S. is estimated at US$70.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$82.5 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Bile Duct Cancer Market - Key Trends and Drivers Summarized

What Makes Bile Duct Cancer So Complex and Challenging?

Bile duct cancer, also known as cholangiocarcinoma, is a rare but highly aggressive form of cancer that originates in the bile ducts, the thin tubes responsible for carrying bile from the liver to the gallbladder and small intestine. But what makes this cancer so particularly challenging? The complexity lies in its insidious nature; bile duct cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed to an advanced stage. By the time symptoms such as jaundice, abdominal pain, or unexplained weight loss appear, the disease is often already at a stage where treatment options are limited. Furthermore, the bile ducts' anatomical location, nestled deep within the liver and surrounded by vital organs, complicates both the diagnosis and surgical intervention. Imaging tests such as MRI, CT scans, and specialized techniques like cholangiography are essential for locating tumors, but they can be inconclusive or challenging to interpret due to the complex structure of the biliary system. This complexity underscores the urgent need for more effective diagnostic tools and early detection strategies in the fight against bile duct cancer.

Why Are Treatment Options for Bile Duct Cancer Limited?

Despite advancements in cancer treatment, why are options for bile duct cancer still so limited? The primary reason is the rarity of the disease, which has led to a lack of extensive research and clinical trials compared to more common cancers. The standard treatment for localized bile duct cancer is surgery, specifically resection of the affected portion of the bile duct or liver. However, surgery is only viable if the cancer is detected early and has not spread to other organs. Unfortunately, due to late diagnosis, many patients are not eligible for surgery, leaving chemotherapy and radiation as the mainstays of treatment. These therapies, while sometimes effective in slowing the progression of the disease, are not curative and often come with significant side effects. In recent years, there has been some progress in the development of targeted therapies and immunotherapy, which aim to attack cancer cells more precisely while sparing healthy tissue. Drugs targeting specific genetic mutations associated with bile duct cancer, such as FGFR2 and IDH1 inhibitors, have shown promise in clinical trials, offering hope for more effective treatments in the future. However, the heterogeneity of the cancer, with its various subtypes and molecular profiles, complicates the development of a one-size-fits-all treatment approach.

What Are the Latest Trends in Bile Duct Cancer Research?

Research into bile duct cancer is intensifying, but what are the latest trends that could change the outlook for patients? One significant trend is the growing focus on personalized medicine. Researchers are increasingly recognizing the importance of genetic profiling in understanding the unique characteristics of each patient’s cancer. By identifying specific genetic mutations and molecular targets, personalized treatment plans can be developed that are more effective than traditional chemotherapy. Another trend is the exploration of immunotherapy, which leverages the body’s immune system to fight cancer. Although still in its early stages for bile duct cancer, clinical trials are investigating the potential of immune checkpoint inhibitors and other immunotherapeutic agents to improve patient outcomes. Additionally, there is a push toward improving early detection methods, with scientists exploring biomarkers in blood and bile that could lead to less invasive and more accurate diagnostic tests. Advancements in imaging technologies, such as PET/CT scans and enhanced MRI techniques, are also contributing to earlier and more precise diagnoses. Moreover, the role of liquid biopsy, which detects cancerous cells or DNA fragments in the blood, is being studied as a potential game-changer in monitoring disease progression and response to treatment in real-time.

What Factors Are Driving the Growth in the Bile Duct Cancer Treatment Market?

The growth in the bile duct cancer treatment market is driven by several factors, reflecting the increasing demand for innovative therapies and diagnostics. One of the primary drivers is the advancement in genomic research, which has led to the identification of actionable genetic mutations that can be targeted with specific drugs. This has opened up new avenues for the development of targeted therapies, providing more effective treatment options for patients with specific genetic profiles. Additionally, the rising prevalence of bile duct cancer, particularly in regions with higher incidences due to risk factors like liver fluke infections, is fueling the demand for better treatment options. Another significant factor is the growing awareness of the disease among healthcare providers and patients, leading to earlier diagnosis and a greater emphasis on early-stage intervention. The increasing availability of advanced diagnostic technologies, such as next-generation sequencing and improved imaging techniques, is also contributing to the market's growth by enabling more accurate and earlier detection of the disease. Furthermore, the expansion of clinical trials and the involvement of pharmaceutical companies in the development of new treatments are accelerating the introduction of novel therapies. As these factors converge, the bile duct cancer treatment market is poised for significant growth, offering hope for improved patient outcomes in the future.

Select Competitors (Total 56 Featured) -

  • AbbVie Inc.
  • Accord Healthcare, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CONMED Corporation
  • Delcath Systems Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Intercept Pharmaceuticals, Inc.
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals USA, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bile Duct Cancer - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bile Duct Cancer Spurs Demand for Advanced Diagnostic Tools
    • Focus on Personalized Medicine Expands Addressable Market Opportunity for Targeted Therapies
    • Advancements in Genomic Research Propel Growth in Precision Oncology Solutions
    • Increasing Awareness of Rare Cancers Strengthens Business Case for Specialized Treatment Options
    • Development of Biomarker-Based Therapies Generates Demand for Companion Diagnostics
    • Innovations in Imaging Technology Drive Adoption of Early Detection Methods
    • Expansion of Clinical Trials for Bile Duct Cancer Accelerates Access to Experimental Treatments
    • Rising Healthcare Expenditure Creates New Opportunities for Advanced Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bile Duct Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Intrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Intrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Intrahepatic Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Extrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Extrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Extrahepatic Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • JAPAN
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • CHINA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • EUROPE
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Bile Duct Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • FRANCE
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • GERMANY
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Bile Duct Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • INDIA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Bile Duct Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Bile Duct Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • AFRICA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030

IV. COMPETITION